Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03

G. D’Addario(Kantonsspital St. Gallen), Daniel Betticher, Daniel Rauch(Washington University in St. Louis), Miklos Pless(Ontario Institute for Cancer Research), Nicolas Mach(University of Geneva), Michel Bihl(University Hospital of Zurich), C. Tapia(University Hospital of Basel), Roger Stupp(Northwestern University), Michael Mayer(Swiss Group For Clinical Cancer Research), Stefanie Lerch(Swiss Group For Clinical Cancer Research), L. Widmer(Triemli Hospital), R. Stahel, Lukas Bubendorf(University of Basel), L.M. Jost(Kantonsspital Baselland Standort Bruderholz), Karin Ribi
Annals of Oncology
December 21, 2007
10.1093/annonc/mdm564
Cited by 43

Related Papers

<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma
|New England Journal of Medicine|2005|7.2k
Tissue microarrays for high-throughput molecular profiling of tumor specimens
|Nature Medicine|1998|4.1k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma
|JAMA|2017|2.5k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k